Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENDRA Life Sciences Inc.NDRA · Entity 8083 | Chief Financial Officer | April 05, 2021 | April 07, 2021 |
| Envoy Medical, Inc.COCH · Entity 7161 | Chief Financial Officer | October 15, 2023 | October 17, 2023 |
| Functional Brands Inc.MEHA · Entity 8693 | Director · Chief Financial Officer | May 18, 2026 | May 20, 2026 |
| Fusemachines Inc.FUSE · Entity 7704 | Chief Financial Officer | September 01, 2026 | September 08, 2026 |
| HeartSciences Inc.HSCS · Entity 7830 | Director | January 12, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENDRA Life Sciences Inc.
Report date April 05, 2021 · Filed April 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.64 · Expires 2031-04-05 | Direct | 25,000 |
Reported balance
After 2021-04-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-05 · Grant · Acquired 25,000 · Balance 25,000 F1: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022.
Envoy Medical, Inc.
Report date October 15, 2023 · Filed October 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2033-10-15 | Direct | 293,250 |
Reported balance
After 2023-10-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-10-15 · Grant · Acquired 293,250 · Balance 293,250 F1: Options to purchase 73,313 shares vest on 10/15/2024, and the remaining 219,937 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 73,313 shares vest on 10/15/2024, and the remaining 219,937 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
Functional Brands Inc.
Report date May 18, 2026 · Filed May 20, 2026
This filing explicitly reported no securities owned.
Fusemachines Inc.
Report date September 01, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 10,000 F1: Restricted Stock Unit ("RSU") award under the issuer's 2025 Omnibus Equity Incentive Plan, which vest on the date of grant. F2: Each RSU represents a right to receive one share of the issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Unit ("RSU") award under the issuer's 2025 Omnibus Equity Incentive Plan, which vest on the date of grant.
F2: Each RSU represents a right to receive one share of the issuer's common stock.
HeartSciences Inc.
Report date January 12, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 15,000 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 15,000 · Balance 15,000 F1: Represents Restricted Stock Units (the "RSUs") granted to the Reporting Person under the Issuer's 2023 Equity Incentive Plan (as amended, the "Plan") pursuant to the approval of the Issuer's board of directors. Each vested RSU shall be settled by delivery to the Reporting Person of one share of the Issuer's common stock, $0.001 par value per share, upon satisfaction of the Conditions (as defined below). F2: The RSUs shall vest subject to the satisfaction of all of the following conditions (the "Conditions"): (i) approval by the Issuer's shareholders of any amendment or modification to or restatement of the Plan, which, among other things, contemplates the award of the RSUs; and (ii) (x) 1/2 of the RSUs shall vest on the one-year anniversary of the grant date (the "Initial Vesting Date") and (y) thereafter, 1/8th of the RSUs shall vest on each subsequent quarterly anniversary of the Initial Vesting Date (each an "Additional Initial Vesting Date" and together with the Initial Vesting Date, the "Vesting Dates"), such that all of the RSUs shall fully vest on the two-year anniversary of the grant date in each case provided that the Reporting Person is continuously serving on the Board through each applicable Vesting Date. F3: 100% of the RSUs shall vest (i) in the event of a Change of Control (as defined in the Plan) or (ii) if the Issuer achieves $250,000 or more of revenue in any fiscal quarter ending after the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units (the "RSUs") granted to the Reporting Person under the Issuer's 2023 Equity Incentive Plan (as amended, the "Plan") pursuant to the approval of the Issuer's board of directors. Each vested RSU shall be settled by delivery to the Reporting Person of one share of the Issuer's common stock, $0.001 par value per share, upon satisfaction of the Conditions (as defined below).
F2: The RSUs shall vest subject to the satisfaction of all of the following conditions (the "Conditions"): (i) approval by the Issuer's shareholders of any amendment or modification to or restatement of the Plan, which, among other things, contemplates the award of the RSUs; and (ii) (x) 1/2 of the RSUs shall vest on the one-year anniversary of the grant date (the "Initial Vesting Date") and (y) thereafter, 1/8th of the RSUs shall vest on each subsequent quarterly anniversary of the Initial Vesting Date (each an "Additional Initial Vesting Date" and together with the Initial Vesting Date, the "Vesting Dates"), such that all of the RSUs shall fully vest on the two-year anniversary of the grant date in each case provided that the Reporting Person is continuously serving on the Board through each applicable Vesting Date.
F3: 100% of the RSUs shall vest (i) in the event of a Change of Control (as defined in the Plan) or (ii) if the Issuer achieves $250,000 or more of revenue in any fiscal quarter ending after the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Jan 13, 2026 01:03 UTC | HeartSciences Inc. HSCS · Entity 7830 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-003616 · ownership.xml · derivative · entry 1 Wells David R. · CIK 0001480371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Represents Restricted Stock Units (the "RSUs") granted to the Reporting Person under the Issuer's 2023 Equity Incentive Plan (as amended, the "Plan") pursuant to the approval of the Issuer's board of directors. Each vested RSU shall be settled by delivery to the Reporting Person of one share of the Issuer's common stock, $0.001 par value per share, upon satisfaction of the Conditions (as defined below). F2 · derivative.exercise_date: The RSUs shall vest subject to the satisfaction of all of the following conditions (the "Conditions"): (i) approval by the Issuer's shareholders of any amendment or modification to or restatement of the Plan, which, among other things, contemplates the award of the RSUs; and (ii) (x) 1/2 of the RSUs shall vest on the one-year anniversary of the grant date (the "Initial Vesting Date") and (y) thereafter, 1/8th of the RSUs shall vest on each subsequent quarterly anniversary of the Initial Vesting Date (each an "Additional Initial Vesting Date" and together with the Initial Vesting Date, the "Vesting Dates"), such that all of the RSUs shall fully vest on the two-year anniversary of the grant date in each case provided that the Reporting Person is continuously serving on the Board through each applicable Vesting Date. F3 · derivative.exercise_date: 100% of the RSUs shall vest (i) in the event of a Change of Control (as defined in the Plan) or (ii) if the Issuer achieves $250,000 or more of revenue in any fiscal quarter ending after the date hereof. F2 · derivative.expiration_date: The RSUs shall vest subject to the satisfaction of all of the following conditions (the "Conditions"): (i) approval by the Issuer's shareholders of any amendment or modification to or restatement of the Plan, which, among other things, contemplates the award of the RSUs; and (ii) (x) 1/2 of the RSUs shall vest on the one-year anniversary of the grant date (the "Initial Vesting Date") and (y) thereafter, 1/8th of the RSUs shall vest on each subsequent quarterly anniversary of the Initial Vesting Date (each an "Additional Initial Vesting Date" and together with the Initial Vesting Date, the "Vesting Dates"), such that all of the RSUs shall fully vest on the two-year anniversary of the grant date in each case provided that the Reporting Person is continuously serving on the Board through each applicable Vesting Date. F3 · derivative.expiration_date: 100% of the RSUs shall vest (i) in the event of a Change of Control (as defined in the Plan) or (ii) if the Issuer achieves $250,000 or more of revenue in any fiscal quarter ending after the date hereof. Read SEC document |
| July 09, 2025 Filed Jul 12, 2025 01:00 UTC | HeartSciences Inc. HSCS · Entity 7830 | GrantStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $4.37 | Not disclosed |
DisclosureSEC source: 0001213900-25-063411 · ownership.xml · derivative · entry 1 Wells David R. · CIK 0001480371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-07-09 F1 · derivative.exercise_price: These options were granted to the Reporting Person effective as of July 9, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors. F1 · price: These options were granted to the Reporting Person effective as of July 9, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors. F2 · derivative.exercise_date: The options shall vest and be exercisable as follows: one-fourth of the options vested on the Effective Date and the remainder of the options shall vest in equal increments thereafter on each successive three-month anniversary of the Effective Date, subject to the Reporting Person's continued service on the Board through each applicable vesting date and subject to the terms of the Issuer's 2023 Equity Incentive Plan, as amended (the "2023 Plan"). F3 · derivative.expiration_date: These options expire ten years from the Effective Date, unless terminated sooner in accordance with the Issuer's 2023 Plan or the underlying options grant agreement. Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 22:17 UTC | HeartSciences Inc. HSCS · Entity 7830 | GrantEmployee Stock Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $3.33 | Not disclosed |
DisclosureSEC source: 0001213900-25-005092 · ownership.xml · derivative · entry 1 Wells David R. · CIK 0001480371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2035-01-16 F1 · derivative.exercise_price: These options were granted to the Reporting Person effective as of January 16, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors. F1 · price: These options were granted to the Reporting Person effective as of January 16, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors. F2 · derivative.exercise_date: The options shall vest and be exercisable as follows: one-fourth of the options vested on the Effective Date and the remainder of the options shall vest in equal increments thereafter on each successive three-month anniversary of the Effective Date, subject to the Reporting Person's continued service on the Board through each applicable vesting date and subject to the terms of the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"). F3 · derivative.expiration_date: These options expire ten years from the Effective Date, unless terminated sooner in accordance with the Issuer's 2023 Plan or the underlying options grant agreement. Read SEC document |
| October 15, 2023 Filed Oct 17, 2023 20:09 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantStock Option (right to buy) · Derivative | 293,250 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001062993-23-019440 · form4.xml · derivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,250 Underlying: Class A Common Stock · 293,250 shares Expires 2033-10-15 F1 · derivative.exercise_date: Options to purchase 73,313 shares vest on 10/15/2024, and the remaining 219,937 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 23:56 UTC | HeartSciences Inc. HSCS · Entity 7830 | GrantDirector Stock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $0.97 | Not disclosed |
DisclosureSEC source: 0000899243-23-009454 · doc4.xml · derivative · entry 1 Wells David R. · CIK 0001480371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-03-20 F1 · derivative.exercise_price: These options were granted to the Reporting Person effective as of March 20, 2023 (the "Effective Date"), pursuant to the approval of the Issuer's board of directors (the "Board") on March 20, 2023. F1 · price: These options were granted to the Reporting Person effective as of March 20, 2023 (the "Effective Date"), pursuant to the approval of the Issuer's board of directors (the "Board") on March 20, 2023. F2 · derivative.exercise_date: The options shall vest in four equal increments, with the first tranche of the options vesting on June 20, 2023 (the "Initial Vesting Date"), with an additional one-fourth of the options vesting on each successive three-month anniversary of the Initial Vesting Date, subject to the Reporting Person's continued service on the Board through each applicable vesting date and subject to the terms of the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"). F3 · derivative.expiration_date: These options expire ten years from the Effective Date, unless terminated sooner in accordance with the 2023 Plan or the underlying options grant agreement. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:10 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001209191-21-025849 · doc4.xml · derivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-04-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 00:15 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | SaleCommon Stock | 34,900 | $0.90 | $31,410.00 |
DisclosureSEC source: 0001209191-21-002370 · doc4.xml · nonDerivative · entry 2 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,003 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units which were granted to the Reporting Person on April 9, 2020. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 00:15 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | SaleCommon Stock | 100 | $0.90 | $90.00 |
DisclosureSEC source: 0001209191-21-002370 · doc4.xml · nonDerivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,903 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units which were granted to the Reporting Person on April 9, 2020. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 12:22 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | OtherWarrants · Derivative | 5,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001209191-20-038681 · doc4.xml · derivative · entry 3 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,051 Underlying: Common Stock · 5,000 shares Expires 2024-12-11 Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 12:22 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | OtherCommon Stock | 5,000 | $0.87 | $4,350.00 |
DisclosureSEC source: 0001209191-20-038681 · doc4.xml · nonDerivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,003 F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 11:38 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | ConversionSeries A Convertible Preferred Stock · Derivative | 8.744 | $1,143.68 Strike: $0.87 | $10,000.34 |
DisclosureSEC source: 0001209191-20-035438 · doc4.xml · derivative · entry 3 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87. F3 · derivative.expiration_date: The Series A Convertible Preferred Stock has no expiration date. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 11:38 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | ConversionCommon Stock | 10,350 | $0.87 | $9,004.50 |
DisclosureSEC source: 0001209191-20-035438 · doc4.xml · nonDerivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 20:39 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantCommon Stock | 79,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024213 · doc4.xml · nonDerivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,653 F1 · shares: Represents restricted stock units granted in lieu of a portion of the Reporting Person's cash salary. Subject to continued employment, the restricted stock units vest each day, pro rata based on the number of days between the grant date and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| January 25, 2020 Filed Jan 28, 2020 22:02 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001209191-20-005185 · doc4.xml · derivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-25 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning January 25, 2021. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:54 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantWarrants · Derivative | 10,051 | Not disclosed Strike: $0.87 | Not disclosed |
DisclosureSEC source: 0001209191-19-060093 · doc4.xml · derivative · entry 3 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,051 Underlying: Common Stock · 10,051 shares Expires 2024-12-11 F4 · price: The Warrants were issued for no additional consideration in connection with the purchase of the Series A preferred stock. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:54 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantSeries A Convertible Preferred Stock · Derivative | 8.744 | $1,143.68 Strike: $0.87 | $10,000.34 |
DisclosureSEC source: 0001209191-19-060093 · doc4.xml · derivative · entry 2 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8.744 Underlying: Common Stock · 10,051 shares Expires not disclosed F2 · derivative.exercise_price: The Series A preferred stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A preferred stock is convertible into common stock at a price per share of $0.87. F3 · derivative.expiration_date: The Series A preferred stock has no expiration date. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:54 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock option (right to buy) · Derivative | 138,375 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-19-060093 · doc4.xml · derivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,375 Underlying: Common Stock · 138,375 shares Expires 2029-12-11 F1 · derivative.exercise_date: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date. Read SEC document |
| September 27, 2019 Filed Sep 30, 2019 20:16 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 10,000 | $1.18 | $11,800.00 |
DisclosureSEC source: 0001209191-19-051091 · doc4.xml · nonDerivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| August 23, 2019 Filed Aug 26, 2019 20:18 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 5,000 | $1.55 | $7,750.00 |
DisclosureSEC source: 0001209191-19-047405 · doc4.xml · nonDerivative · entry 2 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.59, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 20:18 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | PurchaseCommon Stock | 5,000 | $1.56 | $7,800.00 |
DisclosureSEC source: 0001209191-19-047405 · doc4.xml · nonDerivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| May 13, 2019 Filed May 15, 2019 21:00 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 56,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001209191-19-030069 · doc4.xml · derivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2029-05-13 F1 · derivative.exercise_date: These Stock Options become exercisable in three equal annual installments beginning on May 13, 2020. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:40 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-18-062953 · doc4.xml · derivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2022-12-13 F1 · derivative.exercise_date: These Stock Options become exercisable in twelve equal quarterly installments beginning on March 13, 2019. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 21:18 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $10,000.00 Strike: $1.68 | $10,000.00 |
DisclosureSEC source: 0001209191-18-058723 · doc4.xml · derivative · entry 2 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By StoryCorp Consulting Disclosed balance after: Not disclosed Underlying: Common Stock · 5,953 shares Expires 2018-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Pursuant to the terms of the Convertible Promissory Note (the "Note"), the principal amount of the Note automatically converted into shares of the Issuer's Common Stock upon the consummation of a Qualified Financing (as defined in the Note) at the lowest per share price at which Common Stock was sold by the Issuer in the Qualified Financing, less a discount of 20%. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 21:18 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | ConversionCommon Stock | 5,953 | $1.68 | $10,001.04 |
DisclosureSEC source: 0001209191-18-058723 · doc4.xml · nonDerivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By StoryCorp Consulting Disclosed balance after: 24,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares of Common Stock were issued upon the conversion of the Convertible Promissory Note described in footnote (2). Read SEC document |
| June 28, 2018 Filed Jul 2, 2018 23:37 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantWarrants · Derivative | 2,480 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001209191-18-040509 · doc4.xml · derivative · entry 2 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By StoryCorp Consulting Disclosed balance after: 2,480 Underlying: Common Stock · 2,480 shares Expires 2021-06-28 F4 · price: The Warrants were issued for no additional consideration in connection with the offer and sale of the Note. Read SEC document |
| June 28, 2018 Filed Jul 2, 2018 23:37 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantConvertible Promissory Note · Derivative | Not disclosed | $10,000.00 | $10,000.00 |
DisclosureSEC source: 0001209191-18-040509 · doc4.xml · derivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By StoryCorp Consulting Disclosed balance after: Not disclosed Underlying: Common Stock · 4,961 shares Expires 2018-12-31 F1 · derivative.exercise_price: The Convertible Promissory Note (the "Note") is convertible into the Issuer's common stock at a conversion price equal to the lesser of (a) the lowest per share price at which common stock is sold by the Issuer in a sale resulting in aggregate gross cash proceeds of at least $7.0 million (a "Qualified Financing"), less a discount of 20%, or (b) $2.016, but in any event no less than a conversion price floor of $1.40, which conversion price is subject to adjustment in certain circumstances in accordance with the terms of the Note. F2 · derivative.exercise_date: The principal amount of the Note will automatically convert into shares of the Issuer's common stock (i) upon the consummation of a Qualified Financing or (ii) if the holders of a majority of the aggregate principal amount of outstanding Convertible Promissory Notes elect to convert such notes at any time until three days prior to a Qualified Financing. Additionally, the reporting person is entitled to convert the principal amount of the Note into common stock (i) at any time until three days prior to the consummation of a Qualified Financing or (ii) if a material Event of Default (as defined in the Note) shall have occurred and be continuing. In each case, conversion is subject to the terms and provisions of the Note. F3 · derivative.underlying_shares: The number of shares of common stock shown in Column 7 assumes a conversion price of $2.016, which is subject to adjustment in certain circumstances (see Footnote 1). Read SEC document |
| May 12, 2017 Filed May 17, 2017 01:16 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 7,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-17-032899 · doc4.xml · derivative · entry 3 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2022-05-12 Read SEC document |
| May 12, 2017 Filed May 17, 2017 01:16 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantStock Options · Derivative | 15,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-17-032899 · doc4.xml · derivative · entry 2 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2021-05-12 F2 · derivative.exercise_date: These Stock Options become exercisable in twelve equal quarterly installments beginning on August 12, 2017. Read SEC document |
| May 12, 2017 Filed May 17, 2017 01:16 UTC | ENDRA Life Sciences Inc. NDRA · Entity 8083 | GrantCommon Stock | 18,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-032899 · doc4.xml · nonDerivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By StoryCorp Consulting Disclosed balance after: 18,833 F1 · price: Award of restricted stock granted pursuant to the Issuer's 2016 Omnibus Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.